Amgen’s Imdelltra BiTEs into SCLC treatment drought

Bispecific T-cell engagers (BiTEs) have a successful track record of receiving accelerated US Food and Drug Administration approvals for hard-to-treat blood malignancies such as multiple myeloma. This success has now been carried across to solid malignancies with Amgen’s Imdelltra (tarlatamab-dlle) having received approval for ES SCLC in patients with disease progression on or after platinum-based chemotherapy, such as cisplatin and etoposide, which has dominated the treatment paradigm for decades.